what is lipo c fat blaster in Lipo-C? Lipo-C

Gene therapy was first approved for a human trial in the United States in 1990 to target genetic defects in adenosine deaminase severe combined immunodeficiency (ADA-SCID) (Wirth et al., 2013)

A detailed history and relevant biochemical investigations were unremarkable for any other etiology of hyperammonemia including the common inborn errors of metabolism (IEM)

Neuron 13:10311037 Nicolletti F, Bruno V, Capani A, Casabona G, Knpfel T (1996) Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders

The 2016 Zubair trial with 50 Pakistani women represents the only placebo-controlled study, showing 37.5% completion rate versus 18.7% placebo (p=0.054), which failed to reach statistical significance